Evogene Ltd. — Form SCHEDULE 13D/A
Filed August 13, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
L.I.A. Pure Capital Ltd. purchased 533,088 American Depositary Shares (ADSs) of Evogene Ltd. across five transactions between August 7–10, 2026, at prices ranging from $0.55 to $0.71 per ADS, for a total of approximately $363,000. Each ADS represents one ordinary share (par value NIS 0.20). This represents an open-market accumulation by a single investor.
Why this rating
Open-market share purchases by an investor; no control threshold disclosed. Insufficient data on total shares outstanding or company market cap to assess materiality.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.